Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

Background OligoG is a low molecular-weight alginate oligosaccharide that improves the viscoelastic properties of cystic fibrosis (CF) mucus and disrupts biofilms, thereby potentiating the activity of antimicrobial agents. The efficacy of inhaled OligoG was evaluated in adult patients with CF. Metho...

Full description

Bibliographic Details
Main Authors: Silke van Koningsbruggen-Rietschel, Jane C. Davies, Tacjana Pressler, Rainald Fischer, Gordon MacGregor, Scott H. Donaldson, Knut Smerud, Nils Meland, Jann Mortensen, Marie Ø. Fosbøl, Damian G. Downey, Astrid H. Myrset, Hugo Flaten, Philip D. Rye, The following investigators and their teams (in alphabetical order) conducted this study., Mary Carroll, Jane Davies, Carsten Schwarz, Nico Derichs, Damian Downey, Olaf Eickmeier, Pal Leyell Finstad, Marie Øbro Fossbøl, Marita Gilljam, Lena Hjelte, Alan Knox, Susanne Nährig, Joachim Riethmüller, Felix C. Ringshausen, AS AlgiPharma, Laura Gow, Joy Conway, William Bennett
Format: Article
Language:English
Published: European Respiratory Society 2020-10-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/6/4/00132-2020.full

Internet

http://openres.ersjournals.com/content/6/4/00132-2020.full

Similar Items